<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019578</url>
  </required_header>
  <id_info>
    <org_study_id>990011</org_study_id>
    <secondary_id>99-C-0011</secondary_id>
    <secondary_id>CDR0000066758</secondary_id>
    <nct_id>NCT00019578</nct_id>
    <nct_alias>NCT00001791</nct_alias>
  </id_info>
  <brief_title>Stereotactic Radiosurgery in Treating Patients With Brain Tumors</brief_title>
  <official_title>Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I
      trial to study the effectiveness of stereotactic radiosurgery in treating patients who have
      brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Establish stereotaxic radiosurgery as a treatment technique at the National
      Institute of Health in patients with intracranial neoplasms.

      II. Assess the response rate, local control, time to progression, pattern of failure, and
      magnetic resonance spectrographic data following this therapy in these patients.

      PROTOCOL OUTLINE: All patients undergo stereotaxic head frame placement, followed by
      stereotaxic radiosurgery on day 1. The dosage of radiation therapy administered is dependent
      on the tumor diameter.

      Patients are followed at 2 and 6 weeks and then every 3 months for 5 years.

      PROJECTED ACCRUAL:

      Up to 30 patients will be accrued for this study within 7-10 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Adult Central Nervous System Germ Cell Tumor</condition>
  <condition>Adult Malignant Meningioma</condition>
  <condition>Adult Medulloblastoma</condition>
  <condition>Adult Noninfiltrating Astrocytoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Craniopharyngioma</condition>
  <condition>Adult Meningioma</condition>
  <condition>Brain Metastases</condition>
  <condition>Adult Ependymoma</condition>
  <condition>Adult Pineal Parenchymal Tumor</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Infiltrating Astrocytoma</condition>
  <condition>Mixed Gliomas</condition>
  <condition>Stage IV Peripheral Primitive Neuroectodermal Tumor</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sterotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Histologically proven intracranial tumor OR Pathologically
        confirmed cancer with metastases to the brain OR Newly discovered brain lesions that are
        amenable to stereotaxic biopsy No more than 3 measurable tumors Only 1 tumor more than 3 cm
        in diameter that requires radiosurgery allowed No tumor more than 4 cm in diameter No tumor
        that involves more than 50% of the brain stem --Prior/Concurrent Therapy-- Biologic
        therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Concurrent
        corticosteroids allowed Radiotherapy: Prior cranial radiotherapy allowed Surgery:
        Radiosurgery to other nonstudy intracranial lesions allowed Prior biopsy and/or subtotal or
        near-total resection allowed --Patient Characteristics-- Age: 18 and over Performance
        status: Karnofsky 70-100% OR ECOG 0-2 Life expectancy: More than 3 months Hematopoietic:
        WBC at least 3,000/mm3 Absolute granulocyte count at least 500/mm3 Hemoglobin at least 10
        g/dL Platelet count at least 50,000/mm3 Hepatic: SGOT or SGPT no greater than 2.5 times
        upper limit of normal (ULN) PT and PTT no greater than 1.5 times ULN No clinically
        significant hepatic dysfunction Renal: Creatinine no greater than 1.3 times ULN
        Cardiovascular: No clinically significant cardiac dysfunction Pulmonary: No clinically
        significant pulmonary dysfunction Other: Not pregnant or nursing Negative pregnancy test No
        clinically significant systemic illness or serious infection that would preclude study
        compliance No other organ dysfunction that would preclude study compliance No history of
        psychiatric disease No allergy to contrast agent Papilledema and motor or sensory deficits
        allowed No contraindications to MRI (e.g., aneurysm clip, implanted neural stimulator,
        implanted cardiac defibrillator, cochlear implant, ocular foreign body or implant, or
        insulin pump)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brian G. Fuller</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult brain tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult infiltrating astrocytoma</keyword>
  <keyword>adult malignant meningioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult noninfiltrating astrocytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult pineal parenchymal tumor</keyword>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>brain metastases</keyword>
  <keyword>brain tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>central nervous system cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>metastatic cancer</keyword>
  <keyword>mixed gliomas</keyword>
  <keyword>site, metastatic cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage IV peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage/type, adult brain tumor</keyword>
  <keyword>unclassified/other cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

